T3D-970

T3D-970 is a preclinical-stage small molecule being developed by T3D Therapeutics for the treatment of Alzheimer's disease. As a follow-on compound to the company's lead candidate, T3D-959, T3D-970 is part of a platform of metabolic regulators that target the peroxisome proliferator-activated receptors (PPAR) delta and gamma. These receptors play a crucial role in glucose and lipid metabolism, as well as inflammatory responses in the brain. By acting as a dual agonist, T3D-970 aims to correct the metabolic dysfunction (often termed "Type 3 Diabetes") and neuroinflammation associated with Alzheimer's disease, potentially offering a disease-modifying approach to neurodegeneration.